RxDoctor Payments Data

Jose Santini, MD

Nephrology · Lake Mary, FLNPI 1902899040

Payments from drug & device makers

$5,120in general payments, 2019–2025

Across 226 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$801
  • Amgen$719
  • Mallinckrodt Hospital Products Inc.$678
  • AstraZeneca$485
  • Otsuka America Pharmaceutical, Inc.$432
  • Baxter Healthcare$283
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,84995%
  • Education$2715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,120 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$317,074
Medicare patients
601
Services billed
3,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol19$32,917
FarxigaDapagliflozin Propanediol19$24,449
ProsolParenteral Amino Acid 20% No.124$2,848
Calcitriol54$1,100
Bumetanide20$1,047
Potassium Citrate ErPotassium Citrate12$800
Losartan Potassium61$693
Hydralazine Hcl43$474
Amlodipine Besylate50$319
Furosemide41$222
Lisinopril38$193
Olmesartan Medoxomil14$149
Allopurinol28$85
Carvedilol14$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$263$32,91719 claims
AstraZenecaFarxiga$485$24,44919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.

Other nephrology in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →